A Look at Madrigal Pharmaceuticals (MDGL) Valuation Following New Rezdiffra Data to Be Presented at AASLD 2025

Madrigal Pharmaceuticals (MDGL) is drawing investor attention after announcing several new data presentations for its liver drug Rezdiffra at the upcoming AASLD The Liver Meeting 2025. The focus is on patients with compensated MASH cirrhosis, where treatment options remain limited.

See our latest analysis for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals’ recent focus on its approved liver drug Rezdiffra and advanced MASH data appears to be stirring up fresh enthusiasm, with investors watching for further clinical progress. The share price has delivered a sharp 38.7% rise over the past three months, helping drive a 33.5% gain year-to-date. In addition, the stock’s 31.1% total shareholder return over the last year underscores sustained long-term momentum as excitement around Rezdiffra continues to build.

Looking for more opportunities in this dynamic sector? It might be the perfect moment to see the full landscape with our comprehensive See the full list for free..

But with shares already soaring in anticipation of further success, is Madrigal still trading at an attractive discount, or has the market already priced in the drug’s next leg of growth?

Most Popular Narrative: 18% Undervalued

Madrigal Pharmaceuticals' most widely followed narrative sees the fair value at $512, a notable premium over the last close price of $418.98. This sharp gap highlights a bull case for strong upside, driven by optimistic projections around growth and profitability over the next several years.

The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity. This increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.

Read the complete narrative.

Want to know the secret fueling this valuation? The forecast hinges on one critical growth lever and a future profit multiple usually reserved for blue-chip leaders. Interested in exactly which bold projections tip the scales on value? Unlock the narrative to see the numbers that make analysts this bullish.

Result: Fair Value of $512 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, potential setbacks such as slow patient uptake or rising competition from new therapies could quickly challenge the optimism surrounding Madrigal’s growth story.

Find out about the key risks to this Madrigal Pharmaceuticals narrative.

Build Your Own Madrigal Pharmaceuticals Narrative

If you think there’s another angle to the Madrigal story or prefer drawing your own conclusions, you can craft a custom narrative in just a few minutes. Do it your way.

A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Don't Miss Out on More Smart Investment Opportunities

Your best stock picks might be just one click away. Use the tools top investors trust and gain an edge before others catch on.

• Earn passive income and secure your portfolio’s future with these 22 dividend stocks with yields > 3% delivering yields above 3%.
• Embrace the AI revolution as these 26 AI penny stocks are transforming industries and setting ambitious growth records.
• Lock in value now by targeting these 831 undervalued stocks based on cash flows with strong cash flows and compelling upside potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com